Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Rituximab (RTX) is an effective agent for both remission induction and maintenance therapy in microscopic polyangiitis (MPA). However, cytomegalovirus (CMV) reactivation due to RTX-induced immunosuppression remains a serious adverse event. Data regarding the high-risk period for CMV reactivation and optimal surveillance strategies are limited.
We retrospectively reviewed 31 patients diagnosed and treated for MPA at our institution between June 1, 2013, and September 30, 2025. Patients were divided into an RTX-treated group (n = 12) and a non-RTX-treated group (n = 19). The incidence and timing of CMV reactivation were compared between the two groups.
CMV reactivation occurred in 8 of 12 patients (67%) in the RTX-treated group and in 6 of 19 patients (32%) in the non-RTX-treated group. Among RTX-treated patients, 5 of 12 (42%) experienced CMV reactivation after RTX administration, all of which occurred during remission induction therapy and within 30 days of the first RTX infusion. One of the five patients developed CMV gastritis, which was the only case of CMV disease observed in this study. There was no significant difference in the reactivation rate between patients who received four weekly doses of RTX and those who received a single dose of the drug for induction therapy. No CMV reactivation was observed during maintenance therapy with RTX administered every six months.
Our findings suggest that CMV reactivation may be more likely to occur within one month after the initial RTX infusion in MPA patients, independent of the number of doses. More vigilant monitoring during this period is warranted.
